Hengrui Medicine Signs MOU for China Rights to Oncolytic Virus Drug

Jiangsu Hengrui Medicine has signed a MOU for China rights to a oncolytic virus therapeutic developed by Japan's Oncolys Biopharma. The drug candidate, Telomelysin (OBP-310), is currently undergoing a Phase I/II trial in Taiwan for liver cancer. Hengrui, an active China in- and out-licensor of novel drug candidates, expects to sign a final contract for the drug in November of this year. Financial details were not disclosed. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: // //